Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Elicio Therapeutics, Inc. (ELTX)
Company Research
Source: Yahoo! Finance
• AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells • Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings • AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024 • $43 million raised in 2024 funds Elicio into the second quarter of 2025 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX)(“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024 and provided recent corporate and clinical up
Show less
Read more
Impact Snapshot
Event Time:
ELTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELTX alerts
High impacting Elicio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ELTX
News
- Elicio Therapeutics Reports Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Elicio Therapeutics Reports Inducement GrantsGlobeNewswire
- Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile VaccinesGlobeNewswire
- Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
ELTX
Sec Filings
- 9/27/24 - Form ARS
- 9/27/24 - Form DEF
- 9/17/24 - Form PRE
- ELTX's page on the SEC website